Connor, Clark & Lunn Investment Management Ltd. Esperion Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$20 Billion
Q4 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 932,008 shares of ESPR stock, worth $1.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

932,008

Previous 711,278 31.03%

Holding current value

$1.7 Million

Previous $1.17 Million 74.77%

% of portfolio

0.01%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	BUY	$1.61 - $3.83 $355,375 - $845,395	220,730 Added 31.03%	932,008 $2.05 Million
Q3 2024 Nov 08, 2024	BUY	$1.61 - $2.73 $475,558 - $806,381	295,378 Added 71.02%	711,278 $1.17 Million
Q2 2024 Aug 09, 2024	BUY	$1.84 - $3.24 $765,256 - $1.35 Million	415,900 New	415,900 $923,000
Q4 2023 Feb 09, 2024	SELL	$0.73 - $3.08 $45,004 - $189,882	-61,650 Reduced 14.9%	352,054 $1.05 Million
Q3 2023 Nov 13, 2023	BUY	$0.96 - $1.79 $216,736 - $404,122	225,767 Added 120.13%	413,704 $405,000
Q2 2023 Aug 10, 2023	SELL	$1.2 - $1.76 $61,922 - $90,819	-51,602 Reduced 21.54%	187,937 $261,000
Q1 2023 May 09, 2023	SELL	$1.46 - $7.3 $64,250 - $321,251	-44,007 Reduced 15.52%	239,539 $380,000
Q4 2022 Feb 10, 2023	BUY	$5.09 - $8.5 $672,093 - $1.12 Million	132,042 Added 87.15%	283,546 $1.77 Million
Q3 2022 Nov 10, 2022	BUY	$5.45 - $8.13 $825,696 - $1.23 Million	151,504 New	151,504 $1.02 Million
Q4 2019 Feb 12, 2020	SELL	$35.4 - $59.82 $788,074 - $1.33 Million	-22,262 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$34.47 - $47.53 $314,538 - $433,711	9,125 Added 69.46%	22,262 $816,000
Q2 2019 Aug 07, 2019	SELL	$40.1 - $52.33 $1.25 Million - $1.63 Million	-31,088 Reduced 70.3%	13,137 $611,000
Q1 2019 May 08, 2019	BUY	$40.11 - $53.57 $73,200 - $97,765	1,825 Added 4.3%	44,225 $1.78 Million
Q4 2018 Feb 12, 2019	BUY	$36.99 - $59.11 $35,140 - $56,154	950 Added 2.29%	42,400 $1.95 Million
Q3 2018 Nov 13, 2018	SELL	$40.74 - $51.41 $646,747 - $816,133	-15,875 Reduced 27.69%	41,450 $1.84 Million
Q2 2018 Aug 02, 2018	BUY	$36.2 - $76.4 $2.08 Million - $4.38 Million	57,325 New	57,325 $2.25 Million

Others Institutions Holding ESPR

# of Institutions

215

Shares Held

129M

Call Options Held

1.78M

Put Options Held

1.27M

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $121M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Esperion Therapeutics, Inc. Transaction History